The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria

Detalhes bibliográficos
Autor(a) principal: Daly, Anne
Data de Publicação: 2020
Outros Autores: Evans, Sharon, Pinto, Alex, Jackson, Richard, Ashmore, Catherine, Rocha, Júlio César, MacDonald, Anita
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/105687
Resumo: Protein is the most satiating macronutrient, increasing secretion of gastrointestinal hormones and diet induced thermogenesis. In phenylketonuria (PKU), natural protein is restricted with approximately 80% of intake supplied by a synthetic protein source, which may alter satiety response. Casein glycomacropeptide (CGMP-AA), a carbohydrate containing peptide and alternative protein substitute to amino acids (AA), may enhance satiety mediated by its bioactive properties. AIM: In a three-year longitudinal; prospective study, the effect of AA and two different amounts of CGMP-AA (CGMP-AA only (CGMP100) and a combination of CGMP-AA and AA (CGMP50) on satiety, weight and body mass index (BMI) were compared. METHODS: 48 children with PKU completed the study. Median ages of children were: CGMP100; (n = 13), 9.2 years; CGMP50; (n = 16), 7.3 years; and AA (n = 19), 11.1 years. Semi-quantitative dietary assessments and anthropometry (weight, height and BMI) were measured every three months. RESULTS: The macronutrient contribution to total energy intake from protein, carbohydrate and fat was similar across the groups. Adjusting for age and gender, no differences in energy intake, weight, BMI, incidence of overweight or obesity was apparent between the groups. CONCLUSION: In this three-year longitudinal study, there was no indication to support a relationship between CGMP and satiety, as evidenced by decreased energy intake, thereby preventing overweight or obesity. Satiety is a complex multi-system process that is not fully understood.
id RCAP_82c244df29eee9247bd36ffd56032e70
oai_identifier_str oai:run.unl.pt:10362/105687
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in PhenylketonuriaglycomacropeptidephenylketonuriaPKUsatietyFood ScienceNutrition and DieteticsSDG 3 - Good Health and Well-beingProtein is the most satiating macronutrient, increasing secretion of gastrointestinal hormones and diet induced thermogenesis. In phenylketonuria (PKU), natural protein is restricted with approximately 80% of intake supplied by a synthetic protein source, which may alter satiety response. Casein glycomacropeptide (CGMP-AA), a carbohydrate containing peptide and alternative protein substitute to amino acids (AA), may enhance satiety mediated by its bioactive properties. AIM: In a three-year longitudinal; prospective study, the effect of AA and two different amounts of CGMP-AA (CGMP-AA only (CGMP100) and a combination of CGMP-AA and AA (CGMP50) on satiety, weight and body mass index (BMI) were compared. METHODS: 48 children with PKU completed the study. Median ages of children were: CGMP100; (n = 13), 9.2 years; CGMP50; (n = 16), 7.3 years; and AA (n = 19), 11.1 years. Semi-quantitative dietary assessments and anthropometry (weight, height and BMI) were measured every three months. RESULTS: The macronutrient contribution to total energy intake from protein, carbohydrate and fat was similar across the groups. Adjusting for age and gender, no differences in energy intake, weight, BMI, incidence of overweight or obesity was apparent between the groups. CONCLUSION: In this three-year longitudinal study, there was no indication to support a relationship between CGMP and satiety, as evidenced by decreased energy intake, thereby preventing overweight or obesity. Satiety is a complex multi-system process that is not fully understood.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNDaly, AnneEvans, SharonPinto, AlexJackson, RichardAshmore, CatherineRocha, Júlio CésarMacDonald, Anita2020-10-15T22:50:11Z2020-09-042020-09-04T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/105687eng1422-8599PURE: 20031774https://doi.org/10.3390/nu12092704info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:50:53Zoai:run.unl.pt:10362/105687Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:40:33.454548Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
title The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
spellingShingle The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
Daly, Anne
glycomacropeptide
phenylketonuria
PKU
satiety
Food Science
Nutrition and Dietetics
SDG 3 - Good Health and Well-being
title_short The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
title_full The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
title_fullStr The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
title_full_unstemmed The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
title_sort The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria
author Daly, Anne
author_facet Daly, Anne
Evans, Sharon
Pinto, Alex
Jackson, Richard
Ashmore, Catherine
Rocha, Júlio César
MacDonald, Anita
author_role author
author2 Evans, Sharon
Pinto, Alex
Jackson, Richard
Ashmore, Catherine
Rocha, Júlio César
MacDonald, Anita
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Daly, Anne
Evans, Sharon
Pinto, Alex
Jackson, Richard
Ashmore, Catherine
Rocha, Júlio César
MacDonald, Anita
dc.subject.por.fl_str_mv glycomacropeptide
phenylketonuria
PKU
satiety
Food Science
Nutrition and Dietetics
SDG 3 - Good Health and Well-being
topic glycomacropeptide
phenylketonuria
PKU
satiety
Food Science
Nutrition and Dietetics
SDG 3 - Good Health and Well-being
description Protein is the most satiating macronutrient, increasing secretion of gastrointestinal hormones and diet induced thermogenesis. In phenylketonuria (PKU), natural protein is restricted with approximately 80% of intake supplied by a synthetic protein source, which may alter satiety response. Casein glycomacropeptide (CGMP-AA), a carbohydrate containing peptide and alternative protein substitute to amino acids (AA), may enhance satiety mediated by its bioactive properties. AIM: In a three-year longitudinal; prospective study, the effect of AA and two different amounts of CGMP-AA (CGMP-AA only (CGMP100) and a combination of CGMP-AA and AA (CGMP50) on satiety, weight and body mass index (BMI) were compared. METHODS: 48 children with PKU completed the study. Median ages of children were: CGMP100; (n = 13), 9.2 years; CGMP50; (n = 16), 7.3 years; and AA (n = 19), 11.1 years. Semi-quantitative dietary assessments and anthropometry (weight, height and BMI) were measured every three months. RESULTS: The macronutrient contribution to total energy intake from protein, carbohydrate and fat was similar across the groups. Adjusting for age and gender, no differences in energy intake, weight, BMI, incidence of overweight or obesity was apparent between the groups. CONCLUSION: In this three-year longitudinal study, there was no indication to support a relationship between CGMP and satiety, as evidenced by decreased energy intake, thereby preventing overweight or obesity. Satiety is a complex multi-system process that is not fully understood.
publishDate 2020
dc.date.none.fl_str_mv 2020-10-15T22:50:11Z
2020-09-04
2020-09-04T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/105687
url http://hdl.handle.net/10362/105687
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1422-8599
PURE: 20031774
https://doi.org/10.3390/nu12092704
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138019970646016